Ramelteon used to treat insomnia can reduce the occurrence of osteoporosis

RUNX2 and BMP2 mRNA levels were significantly higher in theRAMEL treatment groups than in the OP group (p<0.05).Conclusion: To take advantage of the peripheral effects of melatonin, RAMEL, aperipheral melatonin agonist, can be used to prevent osteoporosis.

📌 3 Key Takeaways

🎯

Objective & Hypothesis:Aim: Melatonin promoted osteoblast differentiation and causes an increase in levelsof markers of bone differentiation and proliferation.

📊

Key Findings & Data:In this study, weinvestigated the preventive effects of the melatonin agonist RAMEL on osteoporosisby radiological, histological, and molecularly.Methods: Groups 1: Control, Group 2: Osteoporosis: Overectomized group (OP),Group 3: OP + ramelteon 2 mg/kg, Group 4: OP + ramelteon 4 mg/kg. 24 animalsunderwent bilateral ovariectomy.

💡

Conclusion & Impact:RUNX2 and BMP2 mRNA levels were significantly higher in theRAMEL treatment groups than in the OP group (p<0.05).Conclusion: To take advantage of the peripheral effects of melatonin, RAMEL, aperipheral melatonin agonist, can be used to prevent osteoporosis.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

Aim: Melatonin promoted osteoblast differentiation and causes an increase in levelsof markers of bone differentiation and proliferation. Ramelteon (RAMEL) activatesmelatonin receptors and binds to these receptors as non-selective. In this study, weinvestigated the preventive effects of the melatonin agonist RAMEL on osteoporosisby radiological, histological, and molecularly.Methods: Groups 1: Control, Group 2: Osteoporosis: Overectomized group (OP),Group 3: OP + ramelteon 2 mg/kg, Group 4: OP + ramelteon 4 mg/kg. 24 animalsunderwent bilateral ovariectomy. RAMEL was administered orally once a day in theprophylactic treatment mode for 8 weeks, 6 weeks after ovariectomy.Results: Fourteen weeks after ovariectomy, there was a significant reduction infemoral bone mineral density (BMD) (g/cm2) in the OP group compared to the controlgroup. Compared to the OP group, RAMEL treatment significantly increased the BMDlevel (p<0.05). Bone matrix protein 2 (BMP2) and runt-related transcription factor 2(RUNX2) mRNA levels were significantly lower in the OP group than in the controlgroup (p<0.05). RUNX2 and BMP2 mRNA levels were significantly higher in theRAMEL treatment groups than in the OP group (p<0.05).Conclusion: To take advantage of the peripheral effects of melatonin, RAMEL, aperipheral melatonin agonist, can be used to prevent osteoporosis.

Özet

Amaç: Melatonin osteoblast farklılaşmasını teşvik eder ve kemik farklılaşması ve proliferasyon belirteçlerinin düzeylerinde artışa neden olur. Ramelteon (RAMEL) melatonin reseptörlerini aktive eder ve bu reseptörlere seçici olmayan şekilde bağlanır. Bu çalışmada melatonin agonisti RAMEL' in osteoporoz üzerindeki önleyici etkileri radyolojik, histolojik ve moleküler olarak araştırıldı. Yöntem: Grup 1: Kontrol, Grup 2: Osteoporoz: Over eksizyonu yapılan grup (OP), Grup 3: OP + ramelteon 2 mg/kg, Grup 4: OP + ramelteon 4 mg/kg. 24 hayvana, bilateral ovariektomi uygulandı. RAMEL, ovariektomiden 6 hafta sonra, 8 hafta boyunca profilaktik tedavi modunda günde bir kez oral yoldan uygulandı. Bulgular: Ovariektomiden on dört hafta sonra, kontrol grubuna kıyasla OP grubunda femoral kemik mineral yoğunluğunda (g/cm2) anlamlı bir azalma oldu. OP grubu ile karşılaştırıldığında, RAMEL tedavisi BMD seviyesini önemli ölçüde artırdı (p<0.05). Bone matrix protein 2 (BMP2) ve runt-related transcription factor 2 (RUNX2) mRNA seviyeleri OP grubunda kontrol grubuna göre anlamlı derecede düşüktü (p<0.05). RUNX2 ve BMP2 mRNA seviyeleri, RAMEL tedavi gruplarında OP grubuna göre anlamlı olarak daha yüksekti (p<0.05). Sonuç: Melatoninin periferik etkilerinden yararlanmak için, bir periferik melatonin agonisti olan RAMEL, osteoporozu önlemek için kullanılabilir

🔖

Cite This Article

MAMAN, A., HALICI, Z., YAYLA, M., KÖSE, A., KÖSE, D., GÜRBÜZ, M. A. (2022). Ramelteon used to treat insomnia can reduce the occurrence of osteoporosis. Acta Medica Alanya, Cilt: 5 - Sayı: 2, 164–170. https://ajindex.com/articles/425789

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (12)

Yildirimturk S, Batu S, Alatli C, Olgac V, Firat D, Sirin Y. The effects of supplemental melatonin administration on the healing of bone defects in streptozotocin-induced diabetic rats. J Appl Oral Sci. 2016
DOI: 10.1590/1678-775720150570 2. Maria S, Samsonraj RM, Munmun F, Glas J, Silvestros M, Kotlarczyk MP et al. Biological effects of melatonin on osteoblast/osteoclast cocultures, bone, and quality of life: Implications of a role for MT2 melatonin receptors, MEK1/2, and MEK5 in melatonin-mediated osteoblastogenesis. J Pineal Res. 2018
DOI: 10.1111/jpi.12465 3. Park KH, Kang JW, Lee EM, Kim JS, Rhee YH, Kim M, Jeong SJ, Park YG, Kim SH. Melatonin promotes osteoblastic differentiation through the BMP/ERK/Wnt signaling pathways. J Pineal Res. 2011
DOI: 10.1111/j.1600-079X.2011.00875.x 4. Hakanson DO, Bergstrom WH. Pineal and adrenal effects on calcium homeostasis in the rat. Pediatr Res. 1990
DOI: 10.1203/00006450-199006000-00006 5. Li T, Jiang S, Lu C, Yang W, Yang Z, Hu W, Xin Z, Yang Y. Melatonin: Another avenue for treating osteoporosis? J Pineal Res. 2019
e12548. DOI: 10.1111/jpi.12548 6. Uslu S, Uysal A, Oktem G, Yurtseven M, Tanyalcin T, Basdemir G. Constructive effect of exogenous melatonin against osteoporosis after ovariectomy in rats. Anal Quant Cytol Histol. 2007
PMID: 17987812 7. Halici M, Oner M, Guney A, Canoz O, Narin F, Halici C. Melatonin promotes fracture healing in the rat model. Eklem Hastalik Cerrahisi. 2010
DOI: 10.1159/000492576 8. Conway S, Canning SJ, Howell HE, Mowat ES, Barrett P, Drew JE, Delagrange P, Lesieur D, Morgan PJ. Characterization of human melatonin mt(1) and MT(2) receptors by CRE-luciferase reporter assay. Eur J Pharmacol. 2000
DOI: 10.1016/s0014-2999(99)00914-0 9. Reppert SM, Weaver DR, Ebisawa T. Cloning and characterization of a mammalian melatonin receptor that mediates reproductive and circadian responses. Neuron. 1994
DOI: 10.1016/0896-6273(94)90055-8 10. Dubocovich ML, Rivera-Bermudez MA, Gerdin MJ, Masana MI. Molecular pharmacology, regulation, and function of mammalian melatonin receptors. Front Biosci. 2003
d1093-108. DOI: 10.2741/1089 11. Dubocovich ML, Markowska M. Functional MT1 and MT2 melatonin receptors in mammals. Endocrine. 2005
DOI: 10.1385/ENDO:27:2:101 12. Sharan K, Lewis K, Furukawa T, Yadav VK. Regulation of bone mass through pineal-derived melatonin-MT2 receptor pathway. J Pineal Res.